Grail (GRAL) stock shot up 33% Thursday, the day after the company announced a partnership with Quest (DGX) to expand ...

The placement of Illumina in China's unreliable entity list could have disruptive implications. Read why I remain bullish on ...

Grail spun off from Illumina last year, and is developing a number of early detection cancer screening products. Last week, Grail said it sees fiscal 2025 sales of its Galleri blood test up 20% to ...

While Illumina completed the takeover of Grail last September, it has maintained the business as a separate subsidiary company while it waits for the outcome of antitrust reviews in the US and Europe.

Barclays downgraded Illumina (ILMN) to Underweight from Equal Weight. Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed ...

Illumina's attempt to prevent the European Commission from carrying out an antitrust review of its $8 billion takeover last year of cancer diagnosis firm Grail has been defeated in an EU court.

The financial results for fiscal year 2024 and Q4 2023 and fiscal year 2023 include the financial results for GRAIL which was spun off on June 24, 2024. "The Illumina team delivered fourth quarter ...

CHICAGO: US cancer diagnostic test maker Grail, which was due to list its shares on the Nasdaq yesterday after being spun out of Illumina, is betting that commercial partnerships with health ...

Amounts represent the impact of GRAIL pre-acquisition net operating losses on GILTI, the utilization of US foreign tax credits, and the Pillar Two global minimum top-up tax, which became effective ...

Barclays downgraded Illumina (ILMN) to Underweight from Equal Weight with a price target of $100, down from $130. The firm sees greater risk to management’s ability to deliver on their plan due ...

Illumina is down 15.2% since the beginning of the year, and at $111.06 per share, it is trading 28.4% below its 52-week high of $155.15 from November 2024. Investors who bought $1,000 worth of ...